IASLC North America Conference on Lung Cancer

The agent has a high affinity and specificity for interleukin-1 beta.

The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.

NLR appeared to be a significant predictor of overall survival, and also showed a trend in favor of progression-free survival, among patients with stage III locally-advanced non-small cell lung cancer.

Sequential afatinib and osimertinib improved median overall survival by almost 3.5 years in patients with EGFR T790M-positive non-small cell lung cancer, with an even greater benefit seen in those with Del19-positive disease.

Metformin appeared to increase glucose uptake in lung cancer cells, according to results from a phase II trial.